AUTHOR=Lou Shike , Cao Zhujun , Chi Wanqing , Wang Xiaoyin , Feng Mingyang , Lin Lanyi , Ding Yezhou , Liu Kehui , Qu Lihong , Zhao Gangde , Bao Shisan , Wang Hui 

TITLE=The safety concerns regarding immune checkpoint inhibitors in liver cancer patients rising mainly from CHB

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 14 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1164309

DOI=10.3389/fphar.2023.1164309

ISSN=1663-9812

ABSTRACT=Aim: To analyze the safety of immune checkpoint inhibitors (ICI) in primary liver cancer patients and identify risk factors for immune-related adverse reactions (irAE).
Methods: The study enrolled 106 patients with primary liver cancer, including 81 with hepatocellular carcinoma and 25 with intrahepatic cholangiocarcinoma. It was analyzed that the differences between groups in irAE occurrence, including those with and without targeted drugs and those who received interventional therapy.
Results: The incidence of irAE was 39%, with thyroid function, liver function, and skin events being the most common. There was no correlation between irAE incidence and liver cancer type, stage, or severity, graded of Child-Pugh score, and BCLC classification. However, overweight was a significant risk factor for irAE, correlating with high BMI. The combination of targeted drugs and/or transcatheter arterial chemoembolization therapy did not increase the incidence of irAE.
Conclusion: Overweight is a potential risk factor for irAE in primary liver cancer patients. However, this is no correlation between irAE incidence and liver cancer type, stage, or severity, or combination of targeted drugs or TACE therapy.